<DOC>
	<DOCNO>NCT03088904</DOCNO>
	<brief_summary>The purpose study investigate compare cell responses influenza vaccination monozygotic ( identical ) dizygotic ( fraternal ) twin determine role genetics environment response flu vaccination .</brief_summary>
	<brief_title>Genetic Environmental Factors Response Influenza Vaccination</brief_title>
	<detailed_description>This phase IV study 120 healthy 12-49 year old adolescent adult volunteer give license seasonal influenza vaccine . There exclusion gender , ethnicity race . The volunteer enrol one 3 group : Group A : Up 40 healthy monozygotic ( MZ ) twin volunteer , 12-49 year old , give seasonal quadrivalent inactivate influenza vaccine ( IIV4 ) . Each volunteer complete total 3 visit : Day 0 ( pre-immunization ) , Day 6-8 Day 28+ 7 ( post-immunization ) . All visit consist draw blood study assay monitor serious adverse event ( SAEs ) . Group B : Up 40 healthy dizygotic ( DZ ) twin volunteer , 12-49 year old , give seasonal quadrivalent inactivate influenza vaccine ( IIV4 ) . Each volunteer complete total 3 visit : Day 0 ( pre-immunization ) , Day 6-8 Day 28+ 7 ( post-immunization ) . All visit consist draw blood study assay monitor serious adverse event ( SAEs ) . Group C : Up 40 healthy monozygotic ( MZ ) twin volunteer , 12-49 year old , randomize within twin pair receive either seasonal quadrivalent inactivate influenza vaccine ( IIV4 ) quadrivalent live , attenuated influenza vaccine ( LAIV4 ) . Each volunteer complete total 3 visit : Day 0 ( pre-immunization ) , Day 6-8 Day 28+ 7 ( post-immunization ) . All visit consist draw blood study assay monitor serious adverse event ( SAEs ) . This group discontinue 2016 due ACIP recommendation use LAIV .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria 1 . Otherwise healthy , 1249 year old , identical ( MZ ) fraternal ( DZ ) twin . 2 . Willing complete informed consent process ( include assent minor 1217 year age , inclusive ) . 3 . Availability followup plan duration study least 28 day immunization . 4 . Acceptable medical history review inclusion/exclusion criterion vital sign . Exclusion Criteria 1 . Prior offstudy vaccination current year 's seasonal influenza vaccine . 2 . Allergy egg egg product , vaccine component , ( include gentamicin , gelatin , arginine MSG LAIV ) 3 . Lifethreatening reaction previous influenza vaccination . 4 . Asthma ( If yes , eligible Group C ) ) . 5 . Active systemic serious concurrent illness , include febrile illness day vaccination . 6 . History immunodeficiency ( include HIV infection ) . 7 . Known suspected impairment immunologic function , include , limited , clinically significant liver disease , diabetes mellitus treat insulin , moderate severe renal disease , chronic disorder , opinion investigator , might jeopardize volunteer safety compliance protocol . 8 . Blood pressure &gt; 150 systolic &gt; 95 diastolic first study visit day vaccination . 9 . Hospitalization past year congestive heart failure emphysema . 10 . Chronic Hepatitis B C. 11 . Recent current use immunosuppressive medication , include systemic glucocorticoid ( corticosteroid nasal spray topical steroid permissible group ; inhale steroid use permissible ) . 12 . In close contact anyone severely weaken immune system require protective environment ( If yes , may ineligible Group C ; exposure person avoid 7 day receipt LAIV ) . 13 . Malignancy , squamous cell basal cell skin cancer ( include solid tumor breast cancer prostate cancer recurrence past year , hematologic cancer leukemia ) . 14 . Autoimmune disease ( include rheumatoid arthritis treat immunosuppressive medication Plaquenil , methotrexate , prednisone , Enbrel ) , opinion investigator , might jeopardize volunteer safety compliance protocol . 15 . History blood dyscrasia , renal disease , hemoglobinopathies require regular medical follow hospitalization precede year . 16 . Use anticoagulation medication Coumadin Lovenox , antiplatelet agent aspirin ( except 325 mg. per day ) , Plavix , Aggrenox must review investigator determine would affect volunteer 's safety . 17 . For child adolescent 17 year age , receive aspirin therapy aspirincontaining product ( If yes , eligible Group C ) . 18 . Receipt blood blood product within past 6 month plan use study . 19 . Medical psychiatric condition occupational responsibility preclude participant compliance protocol . 20 . Receipt inactivate vaccine 14 day prior study enrollment , plan vaccination prior completion last study visit ( ~ 28 day study vaccination ) . 21 . Receipt live , attenuated vaccine within 60 day prior enrollment plan vaccination prior completion last study visit ( ~ 28 day study vaccination ) . 22 . Need allergy immunization ( postpone ) study period . 23 . Has take influenza antiviral medication within 48 hour prior study vaccination ( If yes , eligible Group C ) . 24 . History GuillainBarr√© syndrome 25 . Pregnant woman 26 . Lactating woman ( If yes , eligible Group C ) . 27 . Use investigational agent within 30 day prior enrollment plan use study . 28 . Donation equivalent unit blood within 6 week prior enrollment plan donation prior completion last visit . 29 . Any condition , opinion investigator , might interfere volunteer safety , study objective ability participant understand comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Inactivated , quadrivalent influenza vaccine</keyword>
	<keyword>Live , attenuate quadrivalent influenza vaccine</keyword>
	<keyword>Monozygotic twin</keyword>
	<keyword>Dizygotic twin</keyword>
	<keyword>Adults</keyword>
	<keyword>Adolescents</keyword>
</DOC>